African-Americans with genotype-1 with chronic hepatitis C respond poorly to pegylated-interferon and ribavirin combination treatment as compared to Caucasians

被引：1
|
作者：
Khan, AA [1 ]
Mutchnick, MG [1 ]
Ehrinpreis, MN [1 ]
Dhar, R [1 ]
Siddiqui, FA [1 ]
机构：
[1] Wayne State Univ, Sch Med, Detroit, MI 48202 USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2005年 / 100卷 / 09期
关键词：
D O I：
10.14309/00000434-200509001-00311
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
311
引用
收藏
页码：S126 / S126
页数：1
相关论文
共 50 条
  • [21] Pegylated Interferon and Ribavirin for the Treatment of Chronic Hepatitis C
    Kemp, William
    Roberts, Stuart
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2011, 3 : 137 - 150
  • [22] African Americans with genotype 1 treated with interferon for chronic hepatitis C have a lower end of treatment response than Caucasians
    Kinzie, JL
    Naylor, PH
    Nathani, MG
    Peleman, RR
    Ehrinpreis, MN
    Lybik, M
    Turner, JR
    Janisse, JJ
    Massanari, M
    Mutchnick, MG
    JOURNAL OF VIRAL HEPATITIS, 2001, 8 (04) : 264 - 269
  • [23] Safety and efficacy of faldaprevir in combination with pegylated interferon-2b and ribavirin in Japanese patients with genotype-1 chronic hepatitis C virus infection
    Nishiguchi, Shuhei
    Urano, Yasuhisa
    Suzaki, Keiko
    Taniguchi, Atsushi
    Scherer, Joseph
    Berger, Kristi L.
    Quinson, Anne-Marie
    Stern, Jerry O.
    Omata, Masao
    HEPATOLOGY RESEARCH, 2017, 47 (03) : E142 - E151
  • [24] Interferon alone or in combination with ribavirin for the treatment of chronic hepatitis C genotype IV
    Shiha, G
    Salem, S
    JOURNAL OF HEPATOLOGY, 2002, 36 : 129 - 129
  • [25] Cost-Effectiveness Assessment of Telaprevir Combination Treatment Compared to Pegylated-Interferon plus Ribavirin Alone in the Management of Chronic Hepatitis C in Treatment-naive Patients
    Brogan, Anita
    Miller, Jeffrey
    Talbird, Sandra
    Thompson, James
    Deniz, Baris
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 : S410 - S410
  • [26] Pegylated interferon and ribavirin for the recurrence of chronic hepatitis C genotype 1 in transplant patients
    Oton, E
    Barcena, R
    Garcia-Garzon, S
    Moreno-Zamora, A
    Moreno, A
    Garcia-Gonzalez, M
    Blesa, C
    Foruny, JR
    Ruiz, P
    TRANSPLANTATION PROCEEDINGS, 2005, 37 (09) : 3963 - 3964
  • [27] Phase 2 study of omega interferon alone or in combination with ribavirin in subjects with chronic hepatitis C genotype-1 infection
    Novozhenov, V.
    Zakharova, N.
    Vinogradova, E.
    Nikitin, I.
    Gorbakov, V.
    Yakovlev, A.
    Pak, S.
    Rafalski, V.
    Bogomolov, P.
    Alessi, T.
    Blanchett, D.
    Lang, W.
    Langecker, P.
    McNally, J.
    McHutchison, J.
    JOURNAL OF HEPATOLOGY, 2007, 46 : S8 - S8
  • [28] SOCS-1 Promoter Methylation and Treatment Response in Chronic Hepatitis C Patients Receiving Pegylated-Interferon/Ribavirin
    Kuo-Chih Tseng
    Jian-Liang Chou
    Hsien-Bin Huang
    Chih-Wei Tseng
    Shu-Fen Wu
    Michael W. Y. Chan
    Journal of Clinical Immunology, 2013, 33 : 1110 - 1116
  • [29] SOCS-1 Promoter Methylation and Treatment Response in Chronic Hepatitis C Patients Receiving Pegylated-Interferon/Ribavirin
    Tseng, Kuo-Chih
    Chou, Jian-Liang
    Huang, Hsien-Bin
    Tseng, Chih-Wei
    Wu, Shu-Fen
    Chan, Michael W. Y.
    JOURNAL OF CLINICAL IMMUNOLOGY, 2013, 33 (06) : 1110 - 1116
  • [30] Phase 2 study of omega interferon alone or in combination with ribavirin in interferon-naive subjects with genotype-1 chronic hepatitis C
    Novozhenov, Vlaclislav
    Zakharova, Natalia
    Vinogradova, Elena
    Nikitin, Igor
    Gorbakov, Vladimir
    Yakovlev, Alexey
    Pak, Sergey
    Rafalski, Vladimir
    Bogomolov, Pavel
    Alessi, Tom
    Blanchett, Dennis
    Menially, John
    Bacon, Bruce R.
    GASTROENTEROLOGY, 2007, 132 (04) : A778 - A778
12345